» Articles » PMID: 30195927

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas

Overview
Publisher Elsevier
Specialties Oncology
Radiology
Date 2018 Sep 10
PMID 30195927
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The number of studies that evaluate treatment margins for high grade gliomas (HGG) are limited. We hypothesize that patients with HGG who are treated with a gross tumor volume (GTV) to planning tumor volume (PTV) expansion of ≤1 cm will have progression-free survival (PFS) and overall survival (OS) rates similar to those treated in accordance with standard protocols by the Radiation Therapy Oncology Group or European Organisation for Research and Treatment of Cancer. Furthermore, the PFS and OS of subgroups within the study population will have equivalent survival outcomes with GTV1-to-PTV1 margins of 1.0 cm and 0.4 cm.

Methods And Materials: Treatment plans and outcomes for patients with pathologically confirmed HGG were analyzed (n = 267). Survival (PFS and OS) was calculated from the time of the first radiation treatment and a χ test or Fisher exact test was used to calculate the associations between margin size and patient characteristics. Survival was estimated using Kaplan-Meier and compared using the log-rank test. All analyses were performed on the univariate level.

Results: The median PFS and OS times were 10.6 and 19.1 months, respectively. By disease, the median PFS and OS times were 8.6 and 16.1 months for glioblastoma and 26.7 and 52.5 months for anaplastic glioma. The median follow-up time was 18.3 months. The treatment margin had no effect on outcome and the 1.0 cm GTV1-PTV1 margin subgroup (n = 212) showed median PFS and OS times of 10.7 and 19.1 months, respectively, and the 0.4 cm margin subgroup (n = 55) 10.2 and 19.3 months, respectively. In comparison with the standard treatment with 2 cm to 3 cm margins, there was not a significant difference in outcomes.

Conclusions: There is no apparent difference in survival when utilizing smaller versus larger margins as defined by the guidelines of the Radiation Therapy Oncology Group and European Organisation for Research and Treatment of Cancer. Although there remains no class I evidence that outcomes after treatment with smaller margins are identical to those after treatment with larger margins, this large series with long-term follow up suggests that a reduction of the margins is safe and further investigation is warranted.

Citing Articles

Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.

Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.

PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.


miR-200 family as new potential prognostic factor of overall survival of patients with WHO G2 and WHO G3 brain gliomas.

Bilski M, Ciesielka M, Orzechowska M, Jarosz B, Calka P, Bilska S Sci Rep. 2024; 14(1):29345.

PMID: 39592656 PMC: 11599569. DOI: 10.1038/s41598-024-80656-z.


The Systemic Inflammation Response Index Efficiently Discriminates between the Failure Patterns of Patients with Isocitrate Dehydrogenase Wild-Type Glioblastoma Following Radiochemotherapy with FLAIR-Based Gross Tumor Volume Delineation.

Senyurek S, Aygun M, Kilic Durankus N, Akdemir E, Sezen D, Topkan E Brain Sci. 2024; 14(9).

PMID: 39335417 PMC: 11430255. DOI: 10.3390/brainsci14090922.


Impact of clinical target volume margin reduction in glioblastoma patients treated with concurrent chemoradiation.

Di Perri D, Hofstede D, Hartgerink D, Terhaag K, Houben R, Postma A Neurooncol Pract. 2024; 11(3):249-254.

PMID: 38737612 PMC: 11085847. DOI: 10.1093/nop/npad071.


Comparison of different target volume delineation strategies based on recurrence patterns in adjuvant radiotherapy for glioblastoma.

Yilmaz M, Kahvecioglu A, Yedekci F, Yigit E, Ciftci G, Kertmen N Neurooncol Pract. 2024; 11(3):275-283.

PMID: 38737611 PMC: 11085836. DOI: 10.1093/nop/npae009.


References
1.
Tome W, Meeks S, Buatti J, Bova F, Friedman W, Li Z . A high-precision system for conformal intracranial radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47(4):1137-43. DOI: 10.1016/s0360-3016(00)00502-2. View

2.
Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

3.
Meeks S, Tome W, Willoughby T, Kupelian P, Wagner T, Buatti J . Optically guided patient positioning techniques. Semin Radiat Oncol. 2005; 15(3):192-201. DOI: 10.1016/j.semradonc.2005.01.004. View

4.
Brandes A, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C . Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol. 2006; 8(3):253-60. PMC: 1871946. DOI: 10.1215/15228517-2006-005. View

5.
Fuller C, Choi M, Forthuber B, Wang S, Rajagiriyil N, Salter B . Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiat Oncol. 2007; 2:26. PMC: 1939706. DOI: 10.1186/1748-717X-2-26. View